
Kevin L Thomas

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/12166422/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Sex Differences in Coronary Artery Bypass Grafting Techniques: A Society of Thoracic Surgeons Database Analysis. Annals of Thoracic Surgery, 2022, 113, 1979-1988.	1.3	38
2	Racial and ethnic disparities in arrhythmia care: A call for action. Heart Rhythm, 2022, 19, 1577-1593.	0.7	7
3	African American-Caucasian American differences in aortic valve replacement in patients with severe aortic stenosis. American Heart Journal, 2021, 234, 111-121.	2.7	2
4	Percutaneous left atrial appendage occlusion: A review of current devices, clinical evidence, patient selection, and post procedural antithrombotic management. Progress in Cardiovascular Diseases, 2021, 66, 92-100.	3.1	3
5	Ablation Versus Drug Therapy for Atrial Fibrillation in Racial and Ethnic Minorities. Journal of the American College of Cardiology, 2021, 78, 126-138.	2.8	28
6	Outcomes for Patients with Anterior Myocardial Infarction and Prior Cardiac Arrest in the Home Automated External Defibrillator Trial (HAT). Resuscitation, 2021, 168, 75-83.	3.0	1
7	Racial and Ethnic Differences in the Management of Atrial Fibrillation. CJC Open, 2021, 3, S137-S148.	1.5	17
8	Racial Differences in AKI Incidence Following Percutaneous Coronary Intervention. Journal of the American Society of Nephrology: JASN, 2021, 32, 654-662.	6.1	9
9	Videos to reduce racial disparities in ICD therapy Via Innovative Designs (VIVID) trial: Rational, design and methodology. American Heart Journal, 2020, 220, 59-67.	2.7	5
10	Safety and efficacy outcomes of left atrial posterior wall isolation compared to pulmonary vein isolation and pulmonary vein isolation with linear ablation for the treatment of persistent atrial fibrillation. American Heart Journal, 2020, 220, 89-96.	2.7	18
11	Catheter ablation of atrial fibrillation in patients with diabetes mellitus. Heart Rhythm O2, 2020, 1, 180-188.	1.7	11
12	Catheter ablation of atrial fibrillation in cardiac amyloidosis. PACE - Pacing and Clinical Electrophysiology, 2020, 43, 913-921.	1.2	14
13	Effectiveness of catheter ablation of atrial fibrillation according to heart failure etiology. Journal of Arrhythmia, 2020, 36, 84-92.	1.2	7
14	Representativeness of a HeartÂFailure Trial by Race and Sex. JACC: Heart Failure, 2019, 7, 980-992.	4.1	30
15	Assessing heterogeneity of treatment effect analyses in health-related cluster randomized trials: A systematic review. PLoS ONE, 2019, 14, e0219894.	2.5	10
16	Predicting atrial fibrillation recurrence after ablation in patients with heart failure: Validity of the APPLE and CAAPâ€AF risk scoring systems. PACE - Pacing and Clinical Electrophysiology, 2019, 42, 1440-1447.	1.2	11
17	Physicians' perceptions of shared decisionâ€making for implantable cardioverterâ€defibrillators: Results of a physician survey. Journal of Cardiovascular Electrophysiology, 2019, 30, 2420-2426.	1.7	8
18	Atrial Fibrillation and Diabetes Mellitus. Circulation: Arrhythmia and Electrophysiology, 2019, 12, e007351.	4.8	9

T

#	Article	IF	CITATIONS
19	Racial differences in long-term outcomes among black and white patients with drug-eluting stents. American Heart Journal, 2019, 214, 46-53.	2.7	6
20	Exploring patient–provider decision-making for use of anticoagulation for stroke prevention in atrial fibrillation: Results of the INFORM-AF study. European Journal of Cardiovascular Nursing, 2019, 18, 280-288.	0.9	16
21	Research Participation of a Professional Organization in Clinical Trials: The Association of Black cardiologists Clinical Trial Investigator Identification Project. Journal of the National Medical Association, 2019, 111, 122-133.	0.8	0
22	Dofetilide dose reductions and discontinuations in women compared with men. Heart Rhythm, 2018, 15, 478-484.	0.7	28
23	Representation of black patients in randomized clinical trials of heart failure with reduced ejection fraction. American Heart Journal, 2018, 197, 43-52.	2.7	27
24	Design and Evaluation of an Interdisciplinary Health Disparities Research Curriculum. Journal of the National Medical Association, 2018, 110, 305-313.	0.8	2
25	Catheter ablation of atrial fibrillation in patients with heart failure and preserved ejection fraction. Heart Rhythm, 2018, 15, 651-657.	0.7	102
26	Catheter Ablation of Mid-Myocardial Ventricular Tachycardia by Simultaneous Unipolar Radiofrequency Ablation With Half-Normal Saline Irrigation. JACC: Clinical Electrophysiology, 2018, 4, 1263-1264.	3.2	4
27	Racial and ethnic differences in the prevalence, management, and outcomes in patients with atrial fibrillation: A systematic review. Heart Rhythm, 2018, 15, 1337-1345.	0.7	68
28	Effectiveness of high rate and delayed detection ICD programming by race: A MADITâ€RIT substudy. Journal of Cardiovascular Electrophysiology, 2018, 29, 1418-1424.	1.7	1
29	Relation of Early Repolarization (J Point Elevation) to Mortality in Blacks (from the Jackson Heart) Tj ETQq1 1 0.7	784314 rg 1.6	BT Overlock
30	Utilization of cardiac resynchronization therapy in eligible patients hospitalized for heart failure and its association with patient outcomes. American Heart Journal, 2017, 189, 48-58.	2.7	29
31	Race and Sex Differences in QRS Interval and Associated Outcome Among Patients with Left Ventricular Systolic Dysfunction. Journal of the American Heart Association, 2017, 6, .	3.7	9
32	Prevalence, Characteristics, and Outcomes of Valvular Heart Disease in Patients With Atrial Fibrillation: Insights From the ORBITâ€AF (Outcomes Registry for Better Informed Treatment for Atrial) Tj ETQq0) 0 0 .r gBT	/Overslock 10
33	Associations Between Blood Pressure and Outcomes Among Blacks in the Jackson Heart Study. Journal of the American Heart Association, 2016, 5, .	3.7	5
34	Stroke Prediction in Atrial Fibrillation. Journal of the American College of Cardiology, 2016, 68, 471-472.	2.8	1
35	Review of venous thromboembolism and race: the generalizability of treatment guidelines for high-risk populations. Journal of Thrombosis and Thrombolysis, 2016, 42, 167-171.	2.1	8
36	Racial/ethnic differences in atrial fibrillation symptoms, treatment patterns, and outcomes: Insights from Outcomes Registry for Better Informed Treatment for Atrial Fibrillation Registry. American Heart Journal, 2016, 174, 29-36.	2.7	82

#	Article	IF	CITATIONS
37	Ventricular Conduction and Long-Term Heart Failure Outcomes and Mortality in African Americans. Circulation: Heart Failure, 2015, 8, 243-251.	3.9	20
38	Clinical outcome as a function of the PR-intervalthere is virtue in moderation: data from the Duke Databank for cardiovascular disease. Europace, 2015, 17, 978-985.	1.7	22
39	Abstract 17673: The Effectiveness of Improved ICD Programming by Race: A MADIT-RIT Sub-study. Circulation, 2015, 132, .	1.6	0
40	Check It, Change It. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 828-834.	2.2	30
41	Rates of Cardiopulmonary Resuscitation Training in the United States. JAMA Internal Medicine, 2014, 174, 194.	5.1	131
42	Differences in Short-Term Versus Long-Term Outcomes of Older Black Versus White Patients With Myocardial Infarction. Circulation, 2014, 130, 659-667.	1.6	30
43	Use of antiarrhythmic drug therapy and clinical outcomes in older patients with concomitant atrial fibrillation and coronary artery disease. Europace, 2014, 16, 1284-1290.	1.7	9
44	Performance measures to promote quality improvement in sudden cardiac arrest prevention and treatment. American Heart Journal, 2013, 165, 862-868.	2.7	11
45	Educational Videos to Reduce Racial Disparities in ICD therapy Via Innovative Designs (VIVID): A randomized clinical trial. American Heart Journal, 2013, 166, 157-163.e2.	2.7	27
46	Check It, Change It. Circulation: Cardiovascular Quality and Outcomes, 2013, 6, 741-748.	2.2	7
47	Racial Differences in the Prevalence and Outcomes of Atrial Fibrillation Among Patients Hospitalized With Heart Failure. Journal of the American Heart Association, 2013, 2, e000200.	3.7	43
48	Assessment of the quality of existing patient educational tools focused on sudden cardiac arrest: a systematic evaluation by the Sudden Cardiac Arrest Thought Leadership Alliance. Patient Preference and Adherence, 2013, 7, 361.	1.8	6
49	Trends in Use of Implantable Cardioverter-Defibrillator Therapy Among Patients Hospitalized for Heart Failure. Circulation, 2012, 125, 1094-1101.	1.6	124
50	Race and gender variation in the QT interval and its association with mortality in patients with coronary artery disease: Results from the Duke Databank for Cardiovascular Disease (DDCD). American Heart Journal, 2012, 164, 434-441.	2.7	49
51	Systematic Review of the Incidence of Sudden Cardiac Death in the United States. Journal of the American College of Cardiology, 2011, 57, 794-801.	2.8	287
52	Association of race/ethnicity with clinical risk factors, quality of care, and acute outcomes in patients hospitalized with heart failure. American Heart Journal, 2011, 161, 746-754.	2.7	83
53	Quality of care for sudden cardiac arrest: Proposed steps to improve the translation of evidence into practice. American Heart Journal, 2011, 162, 222-231.	2.7	9
54	Racial differences in long-term survival among patients with coronary artery disease. American Heart Journal, 2010, 160, 744-751.	2.7	55

#	Article	IF	CITATIONS
55	Addressing disparities in sudden cardiac arrest care and the underutilization of effective therapies. American Heart Journal, 2010, 160, 605-618.e1.	2.7	21
56	Amiodarone use after acute myocardial infarction complicated by heart failure and/or left ventricular dysfunction may be associated with excess mortality. American Heart Journal, 2008, 155, 87-93.	2.7	33
57	Use of Cardiac Resynchronization Therapy in Patients Hospitalized With Heart Failure. Circulation, 2008, 118, 926-933.	1.6	89
58	Racial Disparity in the Utilization of Implantable-Cardioverter Defibrillators Among Patients With Prior Myocardial Infarction and an Ejection Fraction of â‰ 9 5%. American Journal of Cardiology, 2007, 100, 924-929.	1.6	72
59	Outcomes by Race and Etiology of Patients With Left Ventricular Systolic Dysfunction. American Journal of Cardiology, 2005, 96, 956-963.	1.6	25
60	Therapies to prevent heart failure post-myocardial infarction. Current Heart Failure Reports, 2005, 2, 174-182.	3.3	19